Leviticus Cardio Announces Successful Completion of Third Chronic Animal Study

Petah Tikva, Israel (ots/PRNewswire) - Leviticus Cardio, inventors
of the versatile transcutaneous Coplanar Energy Transfer (CET) system
for use with implanted left ventricular assist devices (LVADs),
announces the successful completion of a 90-day preclinical chronic
animal study to evaluate its CET technology in combination with a
commercial heart pump. The trial was conducted at a renowned animal
facility operated by the Catholic University of Leuven, in Belgium.
This study marked the third successful trial of the Leviticus CET
used in conjunction with a commercial heart pump.

This important achievement paves the way for first in human (FIH),
expected in a matter of months.

"The successful completion of this third long-term chronic trial
utilizing the Jarvik 2000 LVAD pump coupled with the Leviticus
wireless CET system, demonstrates the desired versatility that
addresses an increasing patient population suffering from advanced
heart failure. Besides the robustness and stability of the system, we
are particularly excited about the excellent outcomes on chronic
animal tissue interactions," states Professor Bart Meyns of [Catholic
University].

"A unique hybrid solution with a retroauricular pedestal bail-out
provides a stand-out safety margin to move the technology to the next
stage. Furthermore, relying on a singular external component may
leverage a significant cost reduction for all mechanical circulatory
support users," adds Associate Professor Jiri Maly, of the Institute
for Clinical and Experimental Medicine (IKEM), Prague.

Michael Zilbershlag, CEO of Leviticus Cardio, comments, "We are
thrilled to have reached this milestone, which validates our
technology's versatility and our go-to-market strategy. It clearly
demonstrates the safety and efficacy of our technology in the
preclinical stage."

Peter Hinchliffe, president and COO of Jarvik Heart Inc., stated:
"The combination of Jarvik Heart's proven VAD with post auricular
pedestal and the Leviticus wireless solution are perfectly suited to
integration providing the safety and immediate practicality of a
truly wireless VAD system."

About Leviticus Cardio

Founded in 2008, Leviticus Cardio (Leviticus-cardio.com) is a
medical device company dedicated to improving the clinical outcome
for patients with an implanted left ventricular assist device (LVAD)
for the treatment of impaired cardiac function. The Company has
received funding from The Trendlines Group, Israel's foremost seed-
and early-stage investment group, a consortium of acclaimed
cardiovascular physicians, private investors and Israel's Innovation
Authority (previously, the Office of the Chief Scientist of the
Ministry of Economy).

About Jarvik Heart

Jarvik Heart, Inc. is a private company that develops miniaturized
heart assist devices for the treatment of severe heart failure. The
company, formed in 1988, is located in Manhattan, where it conducts
development and manufacturing activities. The Jarvik 2000®
Ventricular Assist Device has successfully sustained and improved the
condition of patients awaiting transplants as well as those who have
chosen the device for lifetime use.

Contact:

Michael Zilbershlag

CEO

Moshe Levy

COO

Press Relations:
Glenn Kenworthy
GlennKenworthy Marketing Consultancy
Tel: +44(0)1296-738-516
E: cgk@glennkenworthy.com

Photo - https://mma.prnewswire.com/media/740537/Leviticus_Cardio_C
ET_system.jpg

ots Originaltext: Leviticus Cardio
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Leviticus Cardio, übermittelt durch news aktuell